InflaRx (IFRX) CEO reports 1,068,908 shares plus option grants
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
InflaRx N.V. Chief Executive Officer Niels Riedemann has filed an initial statement of beneficial ownership, detailing his current equity position in the company. He directly holds 1,068,908 Ordinary Shares and multiple stock option awards over additional Ordinary Shares at exercise prices ranging from $0.0152 to $2.44 per share, with expirations extending through 2050.
Most of these options were granted between 2012 and 2025 and are described as fully vested and exercisable as of the filing date. A January 6, 2026 option grant vests in four equal quarterly installments of 158,750 shares, subject to continued service, and a separate performance stock option grant tied to that date will vest in two 50% tranches based on a specified financing event before the fourth quarter of 2026 and the average Ordinary Share price in the fourth quarter of 2026 exceeding $1.50.
Positive
- None.
Negative
- None.
Insider Trade Summary
14 transactions reported
Mixed
14 txns
Insider
Riedemann Niels
Role
Chief Executive Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Performance Stock Option (Right to Buy) | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 126,005 shares (Direct);
Performance Stock Option (Right to Buy) — 190,500 shares (Direct);
Ordinary Shares — 1,068,908 shares (Direct)
Footnotes (1)
- This option was granted on November 15, 2012 and is fully vested and exercisable as of the date hereof. This option was granted on November 18, 2016 and is fully vested and exercisable as of the date hereof. This option was granted on December 13, 2017 and is fully vested and exercisable as of the date hereof. This option was granted on November 20, 2018 and is fully vested and exercisable as of the date hereof. This option was granted on January 4, 2021 and is fully vested and exercisable as of the date hereof. This option was granted on July 2, 2021 and is fully vested and exercisable as of the date hereof. This option was granted on January 12, 2022 and is fully vested and exercisable as of the date hereof. This option was granted on November 21, 2022 and is fully vested and exercisable as of the date hereof. This option was granted on January 24, 2023 and is fully vested and exercisable as of the date hereof. This option was granted on January 5, 2024 and is fully vested and exercisable as of the date hereof. This option was granted on January 3, 2025 and is fully vested and exercisable as of the date hereof. This option was granted on January 6, 2026 and will vest and become exercisable in four equal installments of 158,750 shares on each quarterly anniversary of such grant date, subject to continued service through such dates. This option shall vest depending upon achievement of the following performance criteria: (i) 50% shall vest if a certain financing event takes place before the fourth quarter of 2026 and (ii) 50% shall vest if the average Ordinary Share price for quarter four of 2026 exceeds $1.50.
FAQ
What does the Form 3 filing by InflaRx (IFRX) CEO report?
The Form 3 reports CEO Niels Riedemann’s existing equity holdings in InflaRx, including 1,068,908 Ordinary Shares and multiple stock option awards. It is an initial ownership statement and does not itself show new share purchases or sales.
What stock options are disclosed for the InflaRx (IFRX) CEO in this filing?
The filing lists several stock option awards over Ordinary Shares with exercise prices from $0.0152 to $2.44 and expiration dates between 2027 and 2050. Many were granted from 2012 through 2025 and are described as fully vested and exercisable as of the filing date.
Are the InflaRx (IFRX) CEO’s options already vested and exercisable?
Most listed options were granted between 2012 and 2025 and are fully vested and exercisable as of the filing date. A January 6, 2026 option grant vests in four equal quarterly installments, subject to continued service, rather than being fully vested immediately.
What performance conditions apply to the InflaRx (IFRX) CEO’s performance stock options?
The performance stock option grant dated January 6, 2026 vests 50% if a specified financing event occurs before the fourth quarter of 2026 and 50% if the average Ordinary Share price for the fourth quarter of 2026 exceeds $1.50, as described in the filing footnotes.
Does this InflaRx (IFRX) Form 3 show any insider buying or selling activity?
The data reflects holdings and option positions, with transaction codes described as unknown and transaction counts categorized as holdings. The transaction summary shows no buy or sell entries, indicating the filing focuses on reporting existing positions rather than new trades.